Altimmune weight loss drug gets fast track greenlight; Hims poised to enter GLP1 race with strategic edge
Altimmune and Hims are both playing in one of the most explosive medical markets of this decade. The weight loss drug arms race has gone full tilt, and while Novo Nordisk and Eli Lilly have soaked up the spotlight with … Read more